Ranbaxy's journey as a company to end after merger with Sun

Ranbaxy Laboratories will cease to exist as a company after completion of the $ 4 billion merger with Sun Pharmaceuticals, although its brands will be kept alive in over 100 markets.

"The Ranbaxy entity will be merged into Sun Pharma and Sun Pharma will be the surviving entity post-merger," a Sun Pharma spokesperson told PTI.

On Ranbaxy's brands, he said: "...Ranbaxy has branded generics in more than 100 markets. We plan to keep these brands alive in most markets...The brand Ranbaxy itself has a rich heritage and value. We would like to preserve that."

Sun Pharma said April 7 it would fully acquire Ranbaxy, which was incorporated in 1961 and went public in 1973. It will offer 0.8 share of Sun Pharma for each Ranbaxy share, representing an implied value of Rs 457 per Ranbaxy share.

After approval by regulators and shareholders, a record date will be set for the share swap, after which the Ranbaxy stock will not be traded on the exchanges.

According to Daiichi Sankyo of Japan, which holds a 63.41 per cent stake in Ranbaxy, the merger is expected to close by the end of 2014.

The Japanese firm expects to get approval from Indian securities exchanges by June end, while shareholder meetings of Sun Pharma and Ranbaxy are expected at the end of August.

Daiichi acquired the Ranbaxy stake in 2008 for about Rs 22,000 crore after the erstwhile promoters, brothers Malvinder and Shivinder Singh, decided to exit.

The Sun Pharma spokesperson also sought to allay fears of large-scale layoffs of Ranbaxy staff.

"The areas of overlap are relatively limited. As a result, integrating sales and marketing across the companies should be possible," the official said.

After closure of the deal, the combined entity will become the largest pharmaceutical company in India, with an estimated combined revenue of $ 4.2 billion, and the fifth-largest speciality generics company in the world.

The entity will have operations in 65 countries, 47 manufacturing plants across five continents, and a significant platform of speciality and generic products marketed globally, including 629 abbreviated new drug applications.

EDITORIAL OF THE DAY

  • Public musn’t pay for domestic servants for our diplomats

    Nothing seems to have changed in the year and half since the fur that flew thick and fast over the case of diplomat Debjani Khobragade and her maid Sa

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

Urs Schoettli

Economic integration in east Asia

As trade agreements within a global framework have become increasingly ...

Rajgopal Nidamboor

Up the ante of your conscious existence

It sounds cryptic, but is not as complex as it ...

Gautam Gupta

The ‘fake’ issue needs to be taken seriously

E-commerce players are witnessing unbelievable growth globally. Competition is increasing ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture